Amphiphilic peptide chaperones and methods of use
The present disclosure provides amphiphilic peptide chaperones. Also provided are their incorporation into pharmaceutical compositions and methods of use for preventing or reducing a source of stress in cells and for the treatment of disorders including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), cataract, age-related macular degeneration (AMD), glaucoma, and retinitis pigmentosa.
1. An amphiphilic peptide chaperone comprising an amino acid sequence having the sequence of LFVIFLVHFSPGRDEDKDEK (SEQ ID NO: 1) or lfviflvhfspgrdedkdek.
2. The amphiphilic peptide chaperone of claim 1 , wherein the chaperone further comprises at least one chemical modification selected from the group consisting of myri stoyl ati on, phosphorylation, acetylation, methylation, glycosylation, ADP-rib osyl ati on, amidation, lipid addition, oxidation, palmitoylation, FLAG tagging, and tetramethylrhodamine labeling.
3. The amphiphilic peptide chaperone of claim 1 , wherein the N-terminus of the amino acid sequence has a CH 3 modification and/or the C-terminus of the amino acid sequence has an NH 2 modification.
4. A pharmaceutical composition, comprising the amphiphilic peptide chaperone of claim 1 .
5. The pharmaceutical composition of claim 4 , wherein the amphiphilic peptide chaperone comprises from about 0.001 to about 99.9% of the total weight of the composition.
6. The pharmaceutical composition of claim 4 , wherein the chaperone is self-assembled with other like chaperones as spherical nanoparticles.